Terms: = Testicular cancer AND MUC16, CA125, CA-125 AND Staging
3 results:
1. Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors.
Castro BGR; Souza CP; Andrade CEMDC; Vieira MA; Andrade DAP; Reis RD
Rev Bras Ginecol Obstet; 2019 Jul; 41(7):440-448. PubMed ID: 31344718
[TBL] [Abstract] [Full Text] [Related]
2. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract] [Full Text] [Related]
3. PET imaging in the management of tumors of testis and ovary: current thinking and future directions.
Basu S; Rubello D
Minerva Endocrinol; 2008 Sep; 33(3):229-56. PubMed ID: 18846028
[TBL] [Abstract] [Full Text] [Related]
